Beckman Daniella 4

What Happened Daniella Beckman, a director of Upstream Bio, was granted a derivative award covering 17,096 shares on June 9, 2026. The filing reports the acquisition price as $0.00 (no cash paid at grant). The award is reported as a derivative interest (e.g., option or RSU) rather than an open-market purchase or sale.

Key Details

• Transaction date: 2026-06-09; Form 4 filed: 2026-06-11.
• Amount: 17,096 shares granted; reported acquisition price: $0.00; total reported value: $0.
• Nature: Derivative award (shares underlying the award/option).
• Vesting: Footnote states the shares underlying this award shall vest in full upon the earlier of (i) June 9, 2027 and (ii) the date of the next Annual Meeting, subject to Beckman’s continued service.
• Shares owned after transaction: Not specified in this filing.
• Timeliness: Filed on 6/11/2026, within the typical 2-business-day window for Section 16 reporting.

Context This is a compensation/retention-type grant to a director, not an outright purchase or sale. Because it’s a derivative award that vests over time and requires continued service, it does not represent immediate share ownership or a cash investment signal. Retail investors typically view grants like this as routine director compensation rather than a direct buy/sell endorsement.